Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter-2 (SGLT-2) inhibitors, oral drugs for the treatment of patients with type 2 diabetes mellitus (T2D), are mainly used to control blood glucose (Shimizu et al., 2019). This evidence concerns the gene SLC5A2 and diabetes mellitus.